Valneva SE
No SEC Form 4 filings for $VALN in the last 30 days.
See all $VALN insider activity →European stocks ended mixed as Middle East conflict and uncertainty around the Strait of Hormuz weighed on sentiment, while easing concerns about Fed rates followed tame US inflation. Stoxx 600 fell 0.21%, with CAC 40 down 0.16% and DAX up 0.53%. UK’s Sage Group rose 4.5%. Valneva jumped 20% after EMA validated its Lyme vaccine application.
Midday Aug. 14 market update: S&P 500 -0.21% to 7,782.65 and Nasdaq -0.50% to 26,664.30, with stocks pressured by falling consumer confidence. Reddit rose 14% after news it will join the S&P 500. Valneva gained 22% on earnings and regulator validation. T-Mobile US fell on a brokerage downgrade.
Pfizer and Valneva said the European Medicines Agency will review their experimental Lyme disease vaccine, PF-07307405. The companies reported trial results showing about 70% effectiveness in people aged 5 and older, with no approved vaccine currently. Valneva shares rose nearly 16% in Paris after the announcement.
Over the past 7 days, alphai's AI scored 10 news stories mentioning VALN (Valneva SE). Coverage has skewed bullish: 9 bullish, 0 neutral, and 1 bearish.
Recent VALN coverage spans regulation, market movers and technology.
EMA validation is a regulatory milestone that can materially re-rate the probability-weighted commercial outlook.
Regulatory validation plus earnings can re-rate the risk profile and improve probability-weighted commercial outlook.
Regulatory review acceptance is a direct catalyst for Valneva, with immediate market reaction already reflected in the reported share move.
A regulatory acceptance milestone plus a large same-day move suggests traders are repricing Valneva’s Lyme vaccine approval probability.
Valneva’s Lyme program reaching Phase 3 results can materially affect its pipeline value and funding/partnering expectations.
alphai scores every news story that mentions VALN with an AI model for sentiment and relevance, and aggregates insider trades from Valneva SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
European stocks ended mixed as Middle East conflict and uncertainty around the Strait of Hormuz weighed on sentiment, while easing concerns about Fed rates followed tame US inflation. Stoxx 600 fell 0.21%, with CAC 40 down 0.16% and DAX up 0.53%. UK’s Sage Group rose 4.5%. Valneva jumped 20% after EMA validated its Lyme vaccine application.
7 min readMidday Aug. 14 market update: S&P 500 -0.21% to 7,782.65 and Nasdaq -0.50% to 26,664.30, with stocks pressured by falling consumer confidence. Reddit rose 14% after news it will join the S&P 500. Valneva gained 22% on earnings and regulator validation. T-Mobile US fell on a brokerage downgrade.
7 min readPfizer and Valneva said the European Medicines Agency will review their experimental Lyme disease vaccine, PF-07307405. The companies reported trial results showing about 70% effectiveness in people aged 5 and older, with no approved vaccine currently. Valneva shares rose nearly 16% in Paris after the announcement.
4 min readEU officials agreed to study an experimental Lyme disease vaccine, according to Pfizer and Valneva. The firms said trials showed about 70% efficacy in ages 5+ and that the European Medicines Agency accepted an approval application for PF-07307405. Valneva shares rose about 16% in Paris trading.
5 min readThe article says reported Lyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 2025 preliminary cases at 7,105, citing PHAC data. It notes no human Lyme vaccine is currently approved. It describes Pfizer and Valneva’s co-developed vaccine PF-07307405 completing Phase 3 as of March 2026, and Moderna’s mRNA-1975 and mRNA-1982 in Phase 2.
6 min readPfizer (PFE) and Valneva (VALN) said the European Medicines Agency validated their marketing authorization application for PF-07307405, a 6-valent OspA-based Lyme vaccine, moving it into formal review. The Phase 3 VALOR trial reported over 70% reduction in Lyme cases in ages 5+, with no safety concerns. Pfizer will manufacture and commercialize if approved.
3 min readPfizer (PFE) and Valneva SE (VALN) said the European Medicines Agency (EMA) has validated their marketing authorization application for PF-07307405, their Lyme disease vaccine candidate. The validation starts the EMA review process, which could affect future regulatory timelines and commercialization prospects.
2 min readValneva shares rose about 15% to €2.81 after the European Medicines Agency validated Valneva and Pfizer’s Lyme disease vaccine marketing application for VLA15, moving it into review. The programme is in late-stage development. Under the Pfizer deal, Valneva could receive $143 million in milestones plus 14% to 22% royalties if approved.
4 min readValneva shares rose 15.6% to €2.837 after the European Medicines Agency validated its marketing authorization application for PF-07307405, a 6-valent Lyme vaccine co-developed with Pfizer. The filing is based on Phase 3 VALOR data showing over 70% efficacy and no major safety issues. The move followed Valneva’s H1 2026 net loss of €63.3 million, while it reiterated €135–€150 million sales guidance and €121.5 million cash.
4 min readPfizer (PFE) and Valneva (VALN/VLA) said the European Medicines Agency validated their marketing authorization application for PF-07307405, a 6-valent OspA-based Lyme disease vaccine candidate. The filing is based on Phase 3 VALOR results showing over 70% efficacy and no safety concerns. EMA will now assess the application.
4 min read
